Telix Pharmaceuticals Ltd. announced the commercial availability of its next-generation prostate cancer imaging agent, Gozellix®, in the United States. Gozellix is a PSMA-PET imaging agent designed to improve access and convenience for prostate cancer patients. It features an extended "hot" shelf-life of up to six hours, allowing greater transportation and clinical administration flexibility. Gozellix can be produced centrally with a cyclotron or locally with a gallium generator, providing enhanced production flexibility. This advancement is expected to improve access for prostate cancer patients and offer greater scheduling flexibility for clinicians. Telix has also applied for Medicare reimbursement to enhance accessibility for eligible patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.